Abstract: An information processing apparatus includes: an obtainment unit configured to obtain a characteristic value of a fed printing medium; and a determination unit configured to determine the fed printing medium as an unlearned printing medium in a case where the characteristic value obtained by the obtainment unit does not correspond to any of multiple types of printing media determined in advance.

Abstract: The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1): wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.

Abstract: A printing apparatus includes a printing head having nozzles configured to eject droplets, a carriage having the printing head mounted thereon, a control unit configured to control the ejection of the droplets from the nozzles, a detection unit configured to detect the droplets ejected from the nozzles, a determination unit configured to determine an ejection state of the nozzles based on the detection result obtained by the detection unit, a reception unit configured to receive a user input to select a mode, and a setting unit configured to set the mode based on the user input, wherein the control unit causes the droplets to be ejected from the nozzles while moving the carriage relative to the detection unit, and the determination unit determines the ejection state of the nozzles based on the detection result of the droplets ejected while moving the carriage relative to the detection unit.

Abstract: A piezoelectric element driving circuit includes: a power supply including a positive electrode outputting a positive voltage and a negative electrode outputting a negative voltage; first and third switching elements including input terminals connected to the positive electrode; second and fourth switching elements including input terminals connected to the negative electrode; a first resistor connecting an output terminal of the first switching element and a first end of the piezoelectric element; a second resistor connecting the first end and an output terminal of the second switching element; a third resistor connecting an output terminal of the third switching element and a second end of the piezoelectric element; a fourth resistor connecting the second end and an output terminal of the fourth switching element, and a controller supplying a first control signal to the first and second switching elements and a second control signal to the third and fourth switching elements.

Abstract: In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.

Abstract: A work content analyzing apparatus of the present embodiment includes a first database storing state information indicating a state of each of one or a plurality of workers in association with time information and identification information of the worker, an estimation unit estimating the work content executed by the worker on the basis of at least two pieces of state information associated with same time in the state information stored in the first database, a specification unit specifying work time spent for the estimated work content on the basis of the state information stored in the first database and the time information associated with the state information, and an analysis unit analyzing the work content on the basis of the estimated work content and the specified work time.

Abstract: Provided is a vaccine for preventing and/or treating infection with human T-cell leukemia virus type 1 (HTLV-1). A lipid particle encapsulating a nucleic acid expressing a gp46 antigen or a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), wherein the lipid comprises a cationic lipid represented by general formula (Ia): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group optionally having one or more C2-C4 alkanoyloxy groups, or a C10-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: A printing apparatus comprising a carriage on which a printhead is mounted, wherein the printhead is configured to discharge droplets onto a printing medium from a nozzle of the printhead while moving the carriage relative to the printing medium is provided. The printing apparatus performs: detecting droplets discharged from the nozzle; controlling discharge of droplets from the nozzle; and determining a discharging state of the nozzle based on a result of detection, wherein droplets are discharged from the nozzle while the carriage is moving, and wherein the control unit determines the discharging state of the nozzle based on comparison of a threshold stored in a storage unit and information related to a discharging state corresponding to that of some of the droplets discharged from the nozzle while the carriage is moving, the information being derived from a result of detection of the droplets.

Abstract: The present disclosure provides a composition for the prophylaxis or treatment of diseases (e.g., infectious disease, allergy or autoimmune disease). The present disclosure provides a composition, a medicament, a kit, and the like for the prophylaxis or treatment of the disease of a test subject. The composition, medicament, kit, and the like contain a non-causative factor antigen component that is neither derived from nor cross-reactive with the causative factor of the disease, and is administered under conditions where a causative factor antigen component derived from and/or cross-reactive with a causative factor of the target disease is present in the target.

Abstract: The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.

Abstract: In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.

Abstract: A complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention. Furthermore, a complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention.

Abstract: To effectively use a memory when a plurality of memories is combined to constitute a memory module. A memory access control unit performs writing by dividing write data and an error correction code thereof into a plurality of memories, and acquires presence or absence of occurrence of a verify error in each of the plurality of memories related to the writing. In a case where the verify errors occur in at least any of the plurality of memories, an error bit length acquisition unit acquires bit lengths of the verify errors from the plurality of memories.

Abstract: The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: Provided are a work content analysis apparatus, method, and program for analyzing a state of congestion or proximity of persons such as workers in an analysis target region such as a factory, for each area in the analysis target region. According to an embodiment a work content analysis apparatus includes a first database, an accumulation unit, and a classification unit. The database stores position information indicative of a position of a person in the analysis target region together with time information, in association with identification information of the person. The accumulation unit acquires a cumulative value in a predetermined item based on the position information and the time information stored in the first database in association with the identification information of the person. The classification unit classifies the each area based on the cumulative value acquired by the accumulation unit.

Abstract: The present invention provides a novel method for the classification of adjuvants. In one embodiment, the present invention provides a method for generating organ transcriptome profiles for adjuvants, said method comprising: (A) a step for obtaining expression data by performing transcriptome analysis for at least one organ of a target organism by using at least two adjuvants; (B) a step for clustering the adjuvants with respect to the expression data; and (C) a step for generating the organ transcriptome profile for the adjuvants on the basis of the clustering.

Abstract: The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: The present disclosure provides a composition for preventing an immune disorder, recovering from an immune disorder, preventing an immune disorder from occurring and preventing or treating a disease, disorder or condition. The present disclosure provides a composition for preventing an immune disorder, recovering from an immune disorder, preventing an immune disorder from occurring and preventing or treating a disease, disorder or condition in a subject, said composition comprising an antigen component, which is specific to the subject (or immunological memory of which remains in the subject), against a component which is different from a causative factor of the disease, disorder or condition.

Abstract: In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.

Abstract: Provided are non-aggregating immunostimulatory oligonucleotides. The present invention also provides a delivery agent for an immunostimulatory-oligonucleotide nucleic acid medicine, said delivery agent including a nucleic acid that contains a phosphorothioated nucleotide. According to another aspect, the present invention further provides an oligonucleotide including a bioactive core, and a nucleic acid that contains a phosphorothioated nucleotide. The present invention yet further provides an immunostimulator including the bioactive core of a type A/D, type B/K, or type C immunostimulatory oligonucleotide.